Blastic Plasmacytoid Dendritic Neoplasm Study Begins for CAR T-Cell Candidate – Rare Disease Report
|
Blastic Plasmacytoid Dendritic Neoplasm Study Begins for CAR T-Cell Candidate
Rare Disease Report Cellectis announced today that the Phase 1 clinical study testing their CAR T-cell therapy, UCART123, to treat blastic plasmacytoid dendritic cell neoplasm (BPDCN) at the MD Anderson Cancer Center has begun, and the first patient was given the drug. Cellectis Starts BPDCN Phase I Trial with Gene-Edited CAR–T Therapy |
